Literature DB >> 3158659

Evidence for two different active sites on human beta-hexosaminidase A. Interaction of GM2 activator protein with beta-hexosaminidase A.

H J Kytzia, K Sandhoff.   

Abstract

Competition experiments were carried out on the hydrolysis of different substrates by beta-hexosaminidase A isolated from human liver. The results show that ganglioside GM2 in the presence of the GM2 activator protein and a new synthetic substrate, 4-methylumbelliferyl-beta-N-acetylglucosaminide 6-sulfate, are hydrolyzed at the same active site on the alpha subunit of beta-hexosaminidase A, whereas 4-methylumbelliferyl-beta-N-acetylglucosaminide is degraded predominantly by a different active site on the beta-subunit. This finding provides for the first time a possible molecular basis for the observation that, in variant B1 of the GM2 gangliosidoses, beta-hexosaminidase A has lost its activity toward GM2 ganglioside and the sulfated artificial substrate while being still able to hydrolyze the unsulfated artificial substrate at a normal rate. Furthermore, the finding that the GM2 activator protein inhibits the degradation of the sulfated substrate by beta-hexosaminidases A and S indicates that the alpha subunit common to both isoenzymes might provide a binding site for the activator protein.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3158659

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  A double mutation in exon 6 of the beta-hexosaminidase alpha subunit in a patient with the B1 variant of Tay-Sachs disease.

Authors:  P J Ainsworth; M B Coulter-Mackie
Journal:  Am J Hum Genet       Date:  1992-10       Impact factor: 11.025

Review 2.  Human biochemical genetics of enzyme proteins in the new age of molecular genetics.

Authors:  D M Swallow; D A Hopkinson
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

3.  Biochemical characterization of beta-hexosaminidase in different biological specimens from eleven patients with GM2-gangliosidosis B1 variant.

Authors:  M G Ribeiro; R A Pinto; M R Dos Santos; M Maia; M C Sá Miranda
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

4.  Hexosaminidase assays.

Authors:  Michaela Wendeler; Konrad Sandhoff
Journal:  Glycoconj J       Date:  2009-11       Impact factor: 2.916

5.  Clinical, enzymatic, and molecular characterisation of a Portuguese family with a chronic form of GM2-gangliosidosis B1 variant.

Authors:  M G Ribeiro; T Sonin; R A Pinto; A Fontes; H Ribeiro; E Pinto; M M Palmeira; M C Sá Miranda
Journal:  J Med Genet       Date:  1996-04       Impact factor: 6.318

6.  An enzyme with properties similar to those of beta-N-acetylhexosaminidase S is expressed in the promyelocytic cell line HL-60.

Authors:  C Emiliani; T Beccari; A Tabilio; A Orlacchio; R Hosseini; J L Stirling
Journal:  Biochem J       Date:  1990-04-01       Impact factor: 3.857

7.  The Val192Leu mutation in the alpha-subunit of beta-hexosaminidase A is not associated with the B1-variant form of Tay-Sachs disease.

Authors:  Y Hou; G Vavougios; A Hinek; K K Wu; P Hechtman; F Kaplan; D J Mahuran
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

Review 8.  The glycosphingolipid hydrolases in the central nervous system.

Authors:  Massimo Aureli; Maura Samarani; Nicoletta Loberto; Rosaria Bassi; Valentina Murdica; Simona Prioni; Alessandro Prinetti; Sandro Sonnino
Journal:  Mol Neurobiol       Date:  2013-11-27       Impact factor: 5.590

Review 9.  Glycosphingolipid degradation and animal models of GM2-gangliosidoses.

Authors:  T Kolter; K Sandhoff
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

10.  Recombinant GM2-activator protein stimulates in vivo degradation of GA2 in GM2 gangliosidosis AB variant fibroblasts but exhibits no detectable binding of GA2 in an in vitro assay.

Authors:  U Bierfreund; T Lemm; A Hoffmann; G Uhlhorn-Dierks; R A Childs; C T Yuen; T Feizi; K Sandhoff
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.